

Workshop: Emerging Research in Uveal Melanoma and Implications for Treatment: Current Status and Future Directions

organized by the

National Cancer Institute
Office of Rare Diseases Research
National Institutes of Health
U.S. Department of Health and Human Services
and the
Cure OM from Melanoma Research Foundation

AGENDA November 17th, 2013

7:00-8:00 Breakfast*

8:00-8:15 Welcome and Goal Setting (15min/speaker followed by discussion)

8:15-10:15 **Session I: Enhancing Understanding of Uveal Melanoma (UM) Biology**

Chair: Magdalena Thurin, National Cancer Institute

1. Mechanisms controlling immune surveillance of UM, Pierre Triozzi, Cleveland Clinic
2. Influence of Ocular Immune Privilege on Immune Surveillance of Intraocular Tumors
Kyle C. McKenna, University of Pittsburgh School of Medicine
3. Clinical activity of ipilimumab for metastatic uveal melanoma, Jason Luke, Dana-Farber Cancer Institute
4. Arylsulfonamide KCN1 inhibits primary and metastatic uveal melanoma growth in an orthotopic mouse model, Erwin G. Van Meir, Emory University
5. Updates from UM TCGA, Jeffrey Gershenwald, MD Anderson Cancer Center

10:15-10:30 Coffee Break*

10:30-12:30 **Session II: Novel Targets and Markers Predictive of Response in UM**

Chair: Sara Selig, the MRF's CURE OM & Brigham & Women's Hospital

1. GNAQ/GNA11 pathway in UM, Boris Bastian, University of California San Francisco
2. Novel (Druggable) G Protein Signaling Targets, J. Silvio Gutkind, National Institute of Dental and Craniofacial Research, National Institutes of Health
3. Functional insights into the role of BAP1 in uveal melanoma and therapeutic targeting, Anne M. Bowcock, National Heart & Lung Institute, Imperial College London, United Kingdom
4. Clinical grade next-generation sequencing of UM, Elisha Roberson, Washington University

5. Targeted Therapy in Uveal Melanoma: Clinical Experience, Takami Sato, Thomas Jefferson University

12:30-1:30 LUNCH*

1:30-3:00 Session III: Design of Clinical Trials Based on Molecularly Targeted Endpoints: Chair: Richard Carvajal, Memorial Sloan-Kettering Cancer Center

1. Targeted Therapy- Ongoing Trials in UM (KIT, IGF1R, VEGF, MEK, HDAC, Bcl-2, mTOR), Richard Carvajal, Memorial Sloan-Kettering Cancer Center
2. Overview of NCI-sponsored Clinical Trials, Howard Streicher, National Cancer Institute
3. Status of currently accruing clinical trials for advanced UM - European trials & Industry trials, Poulam Patel, University of Nottingham, United Kingdom

3:00-3:15 Coffee Break*

3:15-5:00 Session IV: Challenges for the Development of Therapy Trials: Panel Discussion: Chair: Keith Flaherty, Massachusetts General Hospital

Richard Carvajal, M.D., Memorial Sloan Kettering Cancer Center

Keith Flaherty, Massachusetts General Hospital

Poulam Patel, M.D., University of Nottingham, United Kingdom

Takami Sato, M.D., Thomas Jefferson University

Elad Sharon, M.D., National Cancer Institute

Jeff Sossman, M.D., Vanderbilt University

Howard Streicher, M.D., National Cancer Institute

Mario Sznoll, MD, Yale University

- Which treatment should be tested? Combination trials? Adjuvant trials?
- Which are lead candidates?
- Which patients should be enrolled? Markers driven trials.
- What defines a positive study? Can we use surrogate markers of survival for quicker answers?
- How many patients are required to prove that a treatment is effective?
- Novel designs and network for clinical trials. Are randomized trials necessary? International cooperation for rapid accrual is required.
- Tissue bank

4:00-4:15 Coffee Break*

4:15-5:00 Future Steps & Recommendations:

- Recommendations and Planning for Next Steps

**Workshop meals/refreshments provided by the Society for Melanoma Research*